Retatrutide alternatives.
10 compounds compared to Retatrutide, ranked by published evidence tier and regulatory status, not by what's marketed hardest.
Retatrutide is the most searched-for drug you cannot get. It is a single peptide engineered to hit three receptors at once, GLP-1, GIP, and glucagon, which is what distinguishes it from the approved single agonist semaglutide and the approved dual agonist tirzepatide. As of mid-2026 it is investigational and not approved by the FDA, EMA, MHRA, or any regulator, still in Phase 3 in Lilly's TRIUMPH program. So people are not looking for an alternative to retatrutide's effects, they are looking for something they can legitimately obtain now. Anything sold as research-use-only retatrutide is unapproved, which makes the approved incretin drugs the real comparison.
Retatrutide (development code LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly for the treatment of obesity and related cardiometabolic disease.
- 01TirzepatideS tierFDA-approvedMounjaro · Zepbound
Acts through the glp-1 receptor agonism pathway, like Retatrutide. FDA-approved.
- 02SurvodutideB tierIn human trialsBI 456906
Acts through the glp-1 receptor agonism pathway, like Retatrutide. In human trials.
- 03MazdutideB tierIn human trialsIBI362 · LY3305677
Acts through the glp-1 receptor agonism pathway, like Retatrutide. In human trials.
- 04SemaglutideS tierFDA-approvedOzempic · Wegovy
Acts through the glp-1 receptor agonism pathway, like Retatrutide. FDA-approved.
- 05LiraglutideS tierFDA-approvedVictoza · Saxenda
Acts through the glp-1 receptor agonism pathway, like Retatrutide. FDA-approved.
- 06CagriSemaC tierIn human trialscagrilintide + semaglutide
Acts through the glp-1 receptor agonism pathway, like Retatrutide. In human trials.
- 07
- 08AOD-9604D tierResearch / preclinical
Same category: metabolic & glp-1. Research / preclinical.
- 09HGH Fragment 176-191F tierResearch / preclinicalhGH frag 176-191 · GH lipolytic fragment
Same category: metabolic & glp-1. Research / preclinical.
- 10
An “alternative” here means a compound that shares Retatrutide's mechanism pathway or sits in the same category, not a marketing substitute. Each is ordered by PepCue's evidence tier (a weighted 0–100 score across human data, safety, replication and regulatory clarity), then by whether it's actually approved. This is a research reference, not medical or purchasing advice: an alternative sitting higher on evidence does not mean it's right, safe, or legal for any given use. Reviewed June 1, 2026.
PepCue keeps every compound, dose and lab in one private, provider-ready timeline, whichever one you land on.